Federal Circuit Affirms Ruling for Janssen in Paliperidone Palmitate Patent Dispute

Litigation Timeline & Procedural History

The appeal was filed in the District of Columbia circuit assignment and adjudicated before the Court of Appeals for the Federal Circuit — the exclusive appellate venue for U.S. patent matters. The Federal Circuit’s specialized jurisdiction over patent law makes its decisions particularly authoritative as national precedent.

The 223-day resolution timeline is notably efficient for Federal Circuit patent appeals, which commonly extend well beyond one year. This relatively fast closure — resulting in dismissal of Teva’s appeal — suggests the appellate panel found the lower court record sufficient to affirm without extensive additional briefing cycles or oral argument deliberation. Specific district court trial-level details and the presiding district judge record were not disclosed in the available case data.

Case Overview

The Parties

The Patent at Issue

At the center of this pharmaceutical patent infringement dispute is **U.S. Patent No. 9,439,906** (Application No. 12/337,144), which covers paliperidone palmitate extended-release injectable suspension formulations. Paliperidone palmitate is an atypical antipsychotic prodrug used for treating schizophrenia and schizoaffective disorder. The patent protects specific formulation parameters — including particle size, concentration, and stabilizer profiles — that enable the once-monthly injectable delivery mechanism critical to Invega Sustenna®’s clinical utility.

• • US 9,439,906 — Paliperidone palmitate extended-release injectable suspension

The Accused Products

The infringement action targeted **Janssen’s Invega Sustenna®** in five dosage strengths — 39 mg, 78 mg, 117 mg, 156 mg, and 234 mg — as well as **Teva’s proposed generic paliperidone palmitate extended-release injectable suspension products** across the same dose range. The commercial stakes are substantial: Invega Sustenna® represents one of the most commercially significant long-acting injectable antipsychotics on the U.S. market.

Legal Representation

Teva was represented by **Kirkland & Ellis, LLP**, with attorneys Christopher T. Jagoe, Jeanna Wacker, John C. O’Quinn, Noah Samuel Frank, and William H. Burgess leading the appellate team — a formidable pharmaceutical litigation bench.

Janssen was represented by **Patterson Belknap Webb & Tyler LLP**, with Andrew D. Cohen, Aron Russell Fischer, Barbara Mullin, J. Jay Cho, and Zhiqiang Liu serving as counsel — a team with deep pharmaceutical patent defense experience.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued an unambiguous disposition: **AFFIRMED**. The appeal was dismissed, confirming the lower court’s infringement findings in favor of Janssen Pharmaceuticals. No specific damages figure was disclosed in the available case record, and the specific terms of any injunctive relief were not separately detailed in the appellate order. The affirmance closes the appellate path for Teva on this particular challenge to U.S. Patent No. 9,439,906.

Verdict Cause Analysis

The underlying action was an **infringement action** — meaning the core litigation question centered on whether Teva’s proposed generic paliperidone palmitate injectable products fell within the scope of Janssen’s patent claims. In pharmaceutical Hatch-Waxman-adjacent litigation contexts, infringement analyses of this type typically turn on:

• Claim construction of formulation parameters (particle size distributions, excipient ratios, pH ranges)
• Literal infringement versus **doctrine of equivalents** analysis for generic product specifications
• Validity defenses including obviousness under 35 U.S.C. § 103 and enablement under § 112

The Federal Circuit’s affirmance signals that none of Teva’s appellate arguments — whether directed at claim construction, infringement findings, or validity — were sufficient to disturb the lower court’s conclusions. While the specific legal reasoning underlying the panel’s affirmance was not fully detailed in the available case data, the clean “affirmed” disposition indicates the appellate court found no reversible error in the record below.

Legal Significance

This outcome carries notable weight for **long-acting injectable (LAI) formulation patents** in the pharmaceutical sector. The Federal Circuit’s willingness to affirm the infringement finding reinforces that:

• **Formulation-specific patents** covering particle characteristics, suspension stability, and dosing parameters remain enforceable against generics that seek to copy clinically equivalent products
• **Appellate challenges** to well-developed infringement records face a high burden under the Federal Circuit’s deferential review standards for factual findings
• The **speed of dismissal** may suggest procedural grounds for appeal termination, underscoring the importance of preserving all trial-level arguments for appellate review

Strategic Takeaways

For Patent Holders (Innovator Pharma Companies):

• Robust prosecution of formulation patents — with detailed claim differentiation and specific parameter claiming — creates durable protection against generic ANDA challenges
• Building a comprehensive trial record on infringement evidence is critical, as Federal Circuit review is highly deferential to lower court factual findings
• LAI antipsychotic patents with multi-dose strength coverage (as here) provide broad commercial protection across a product franchise

For Accused Infringers (Generic Manufacturers):

• Appellate strategy must identify clear legal errors — not merely re-argue factual disputes — to succeed at the Federal Circuit
• Design-around opportunities in LAI formulations require meaningful differentiation in particle size specifications, excipient profiles, or manufacturing processes
• Early freedom-to-operate (FTO) analysis of competitor formulation patents should assess claim scope across all commercially relevant dose strengths

For R&D Teams:

• Long-acting injectable formulation space carries significant patent density; thorough FTO clearance before IND filing is essential
• Particle size and suspension parameter claims represent a primary infringement risk zone in this technology area

Industry & Competitive Implications

The Federal Circuit’s affirmance in *Teva v. Janssen* has direct market consequences for both parties. For **Janssen**, the ruling preserves patent exclusivity over Invega Sustenna® at all five commercial dose strengths, extending the competitive moat for one of the pharmaceutical industry’s leading antipsychotic products. This outcome supports continued premium pricing and market share insulation from Teva’s proposed generic entry.

For **Teva**, the dismissal delays — and potentially forecloses — a significant generic market opportunity in the long-acting injectable antipsychotic space. Given the scale of the Invega Sustenna® franchise, this represents a materially consequential outcome for Teva’s generic pipeline strategy.

More broadly, this case reflects a continuing **trend of appellate affirmance in pharmaceutical formulation patent disputes**, where Federal Circuit panels have consistently upheld well-supported infringement findings from the district court level. For companies developing generic LAI antipsychotics or related psychiatric formulations, this ruling signals that **formulation patents with specific physicochemical claim limitations** present substantial litigation risk without clear product differentiation.

Licensing negotiations in the LAI antipsychotic space will likely reflect the strengthened position this outcome creates for Janssen’s IP portfolio.

Frequently Asked Questions

What patent was at issue in Teva v. Janssen (Case No. 25-1228)?

The case involved U.S. Patent No. 9,439,906 (Application No. 12/337,144), covering paliperidone palmitate extended-release injectable suspension formulations underlying Janssen’s Invega Sustenna® product.

What was the Federal Circuit’s ruling?

The Court of Appeals for the Federal Circuit affirmed the lower court’s infringement finding and dismissed Teva’s appeal on July 8, 2025.

How does this ruling affect generic paliperidone palmitate products?

The affirmance blocks Teva’s proposed generic paliperidone palmitate extended-release injectable products across the 39 mg, 78 mg, 117 mg, 156 mg, and 234 mg dose strengths, preserving Janssen’s market exclusivity for Invega Sustenna®.